Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30059113 | 1.00 | LMNA (0.57) | LMNATNKSPTGER3KMT2AMEN1 | |
| SCHEMBL7631274 | 1.00 | LMNA (0.57) | LMNATNKSPTGER3KMT2AMEN1 | |
| SCHEMBL29408442 | 1.00 | LMNA (0.57) | LMNATNKSPTGER3KMT2AMEN1 | |
| SCHEMBL542484 | 0.86 | LMNA (0.70) | LMNATNKSPTGER3KMT2AMEN1 | |
| SCHEMBL542713 | 0.76 | PTGER3 (0.49) | LMNATNKSPTGER3KMT2AMEN1 | |
| SCHEMBL4384462 | 0.75 | ALDH1A1 (0.59) | LMNATNKSKMT2AMEN1ALDH1A1 | |
| SCHEMBL542865 | 0.75 | ALDH1A1 (0.59) | LMNATNKSKMT2AMEN1ALDH1A1 | |
| SCHEMBL4384456 | 0.75 | ALDH1A1 (0.59) | LMNATNKSKMT2AMEN1ALDH1A1 | |
| SCHEMBL9822728 | 0.74 | TNKS (0.51) | LMNATNKSPTGER3KMT2AMEN1 | |
| SCHEMBL9823335 | 0.74 | LMNA (0.55) | LMNATNKSPTGER3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 770 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12370191-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2025-05-01 | — | — | US | disclosed |
| US-12171762-B2 | Sleep disorder treatment and prevention | PURDUE PHARMA L.P. (US) | 2024-12-24 | — | — | US | disclosed |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-20240058333-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11845759-B2 | Opioid compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2023-12-19 | — | — | US | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058333-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | HCRTR1, HCRTR2, MTNR1A | LMNA 1262/4885TNKS 4155/4885PTGER3 1184/4885 |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | CRY1, PER2, SLC6A1 | LMNA 2057/4885TNKS 4732/4885PTGER3 730/4885 |
| US-12370191-B2 | Treatment and prevention of sleep disorders | HCRTR1, HCRTR2, MTNR1A | LMNA 1262/4885TNKS 4155/4885PTGER3 1184/4885 |
| US-11845759-B2 | Opioid compounds and uses thereof | OPRL1, OPRK1, OPRM1 | LMNA 4371/4885TNKS 3117/4885PTGER3 340/4885 |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | HCRTR2, HCRTR1, CRY1 | LMNA 831/4885TNKS 4763/4885PTGER3 1467/4885 |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | STAT3, JAK2, STAT6 | LMNA 3396/4885TNKS 555/4885PTGER3 430/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | LMNA 3648/4885TNKS 2194/4885PTGER3 124/4885 |
| US-12171762-B2 | Sleep disorder treatment and prevention | HCRTR2, HCRTR1, CRY1 | LMNA 831/4885TNKS 4763/4885PTGER3 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.